Abstract
In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib. We compared the impact of these treatments on health-related quality of life (HRQoL).
Patients were randomized 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off). Patient-reported outcomes were assessed using the EORTC QLQ-C30 questionnaire at Day (D)1, and D29 of all cycles until treatment discontinuation. Change from baseline was calculated. Time without symptoms or toxicity (TWiST) was estimated as the mean number of days without progression, death, or grade ≥3 treatment-emergent adverse events per patient over one year of follow-up.
Questionnaire completion at baseline was 88.1% (199/226) for ripretinib and 87.7% (199/227) for sunitinib and remained high for enrolled patients throughout treatment. Patients receiving sunitinib demonstrated within-cycle variation in self-reported HRQoL, corresponding to the on/off dosing regimen. Patients receiving ripretinib reported better HRQoL at D29 assessments than patients receiving sunitinib on all scales except constipation. HRQoL was similar between treatments at D1 assessments, following two weeks without treatment for sunitinib patients. TWiST was greater for ripretinib patients (173 versus 126 days).
Patients receiving ripretinib experienced better HRQoL than patients receiving sunitinib during the dosing period and similar HRQoL to patients who had not received sunitinib for two weeks for all QLQ-C30 domains except constipation. Ripretinib may provide clinically meaningful benefit to patients with advanced GIST previously treated with imatinib.
•Health-related quality of life was evaluated in the INTRIGUE (NCT03673501) study•Patients with advanced GIST received ripretinib or sunitinib•Patients taking ripretinib generally reported less reduction in quality of life•Patients taking ripretinib reported more time without treatment toxicity•Ripretinib may provide clinically meaningful benefit to patients with advanced GIST
